PT  - JOURNAL ARTICLE
AU  - Samuel P. C. Brand
AU  - Rabia Aziza
AU  - Ivy K. Kombe
AU  - Charles N. Agoti
AU  - Joe Hilton
AU  - Kat S. Rock
AU  - Andrea Parisi
AU  - D. James Nokes
AU  - Matt J. Keeling
AU  - Edwine W. Barasa
TI  - Forecasting the scale of the COVID-19 epidemic in Kenya
AID  - 10.1101/2020.04.09.20059865
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.09.20059865
4099  - http://medrxiv.org/content/early/2020/04/16/2020.04.09.20059865.short
4100  - http://medrxiv.org/content/early/2020/04/16/2020.04.09.20059865.full
AB  - Background The first COVID-19 case in Kenya was confirmed on March 13th, 2020. Here, we provide forecasts for the potential incidence rate, and magnitude, of a COVID-19 epidemic in Kenya based on the observed growth rate and age distribution of confirmed COVID-19 cases observed in China, whilst accounting for the demographic and geographic dissimilarities between China and Kenya.Methods We developed a modelling framework to simulate SARS-CoV-2 transmission in Kenya, KenyaCoV. KenyaCoV was used to simulate SARS-CoV-2 transmission both within, and between, different Kenyan regions and age groups. KenyaCoV was parameterized using a combination of human mobility data between the defined regions, the recent 2019 Kenyan census, and estimates of age group social interaction rates specific to Kenya. Key epidemiological characteristics such as the basic reproductive number and the age-specific rate of developing COVID-19 symptoms after infection with SARS-CoV-2, were adapted for the Kenyan setting from a combination of published estimates and analysis of the age distribution of cases observed in the Chinese outbreak.Results We find that if person-to-person transmission becomes established within Kenya, identifying the role of subclinical, and therefore largely undetected, infected individuals is critical to predicting and containing a very significant epidemic. Depending on the transmission scenario our reproductive number estimates for Kenya range from 1.78 (95% CI 1.44 −2.14) to 3.46 (95% CI 2.81-4.17). In scenarios where asymptomatic infected individuals are transmitting significantly, we expect a rapidly growing epidemic which cannot be contained only by case isolation. In these scenarios, there is potential for a very high percentage of the population becoming infected (median estimates: >80% over six months), and a significant epidemic of symptomatic COVID-19 cases. Exceptional social distancing measures can slow transmission, flattening the epidemic curve, but the risk of epidemic rebound after lifting restrictions is predicted to be high.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by: the National Institute for Health Research (NIHR) (project reference 17/63/82) using UK aid from the UK Government to support global health research; Wellcome Trust (Grant 102975) and a Wellcome Trust core award grant to KEMRI-Wellcome Trust Research Programme (number 203077). The authors Charles N. Agoti and Ivy K. Kombe were supported by the Initiative to Develop African Research Leaders (IDeAL)through the DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107769/Z/10/Z] and the UK government. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, AAS, NEPAD Agency, Wellcome Trust or the UK Department of Health and Social Care.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used in forecasts, and all simulation code, is available at KenyaCoV repository https://github.com/SamuelBrand1/KenyaCoV https://github.com/SamuelBrand1/KenyaCoV